Wei Xiong
- Cancer Research top 5%
- Cancer, Hypoxia, and Metabolism 8
- MicroRNA in disease regulation 6
- Oncology top 5%
- HER2/EGFR in Cancer Research 9
- CAR-T cell therapy research 6
-
- Monoclonal and Polyclonal Antibodies Research 6
- Molecular Biology top 10%
- Mitochondrial Function and Pathology 10
- RNA Interference and Gene Delivery 6
- RNA modifications and cancer 6
- Co-authors
- Zhiqiang AnNingyan ZhangKyoji TsuchikamaYasuaki AnamiChisato M. YamazakiJohn C. FangShuang WangCecily P. Vaughn
- Partner nations
- ChinaUnited StatesCanada
In The Last Decade
Wei Xiong
79 papers receiving 2.5k citations
Hit Papers
Peers
Comparison fields: 5 of 122
- Cancer Research 512
- Oncology 845
- Radiology, Nuclear Medicine and Imaging 381
- Molecular Biology 1.1k
- Health, Toxicology and Mutagenesis 219
Countries citing papers authored by Wei Xiong
This map shows the geographic impact of Wei Xiong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wei Xiong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wei Xiong more than expected).
Fields of papers citing papers by Wei Xiong
This network shows the impact of papers produced by Wei Xiong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wei Xiong. The network helps show where Wei Xiong may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Wei Xiong, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2025 | 1 | |
| 3 | 2025 | 4 | |
| 4 | 2024 | 0 | |
| 5 | 2024 | 1 | |
| 6 | 2022 | 36 | |
| 7 | 2021 | 16 | |
| 8 | Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistancebreakdown → | 2021 | 210 |
| 9 | 2021 | 14 | |
| 10 | 2021 | 19 | |
| 11 | 2019 | 2 | |
| 12 | 2018 | 18 | |
| 13 | 2017 | 69 | |
| 14 | 2016 | 84 | |
| 15 | 2014 | 59 | |
| 16 | 2012 | 23 | |
| 17 | 2012 | 5 | |
| 18 | 2011 | 321 | |
| 19 | 2007 | 21 | |
| 20 | 2004 | 6 |
About Wei Xiong
Wei Xiong is a scholar working on Cancer Research, Oncology and Molecular Biology, having authored 84 papers that have together received 2.5k indexed citations. Recurring topics across this work include Mitochondrial Function and Pathology (10 papers), HER2/EGFR in Cancer Research (9 papers), Cancer, Hypoxia, and Metabolism (8 papers), RNA Interference and Gene Delivery (6 papers), RNA modifications and cancer (6 papers), MicroRNA in disease regulation (6 papers), Monoclonal and Polyclonal Antibodies Research (6 papers) and CAR-T cell therapy research (6 papers). The work is most often cited by research in Cancer Research (512 citations), Oncology (845 citations) and Radiology, Nuclear Medicine and Imaging (381 citations). Wei Xiong has collaborated with scholars based in China, United States and Canada. Frequent co-authors include Zhiqiang An, Ningyan Zhang, Kyoji Tsuchikama, Yasuaki Anami, Chisato M. Yamazaki, John C. Fang, Shuang Wang, Cecily P. Vaughn, Karen A. Heichman and Frederica P. Perera. Their work appears in journals such as Nature Communications, Blood and PLoS ONE.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.